SLC44A1 and Alzheimer disease: Recent studies have suggested that the inhibition of CTL1-mediated choline uptake in SIM-A9 cells suppresses the M1 phenotype and activates the M2 phenotype [13], and CTL1 expressed in microglia has attracted attention as a therapeutic target molecule for inflammatory diseases associated with microglial activation such as AD.